OptimizeRx Corporation Common Stock earnings per share and revenue
On Nov 06, 2025, OPRX reported earnings of 0.20 USD per share (EPS) for Q3 25, beating the estimate of 0.04 USD, resulting in a 342.48% surprise. Revenue reached 26.07 million, compared to an expected 24.31 million, with a 7.23% difference. The market reacted with a -17.37% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 31.72 million USD, implying an increase of 15.00% EPS, and increase of 21.70% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Simulations Plus, Inc.
Report Date
Jan 08, 2026 For Q1 26
Estimate
$0.13
Actual
$0.03
Surprise
-77.15%
FAQ
What were OptimizeRx Corporation Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, OptimizeRx Corporation Common Stock reported EPS of $0.20, beating estimates by 342.48%, and revenue of $26.07M, 7.23% above expectations.
How did the market react to OptimizeRx Corporation Common Stock's Q3 2025 earnings?
The stock price moved down -17.37%, changed from $18.94 before the earnings release to $15.65 the day after.
When is OptimizeRx Corporation Common Stock expected to report next?
The next earning report is scheduled for Mar 10, 2026.
What are the forecasts for OptimizeRx Corporation Common Stock's next earnings report?
Based on 9
analysts, OptimizeRx Corporation Common Stock is expected to report EPS of $0.23 and revenue of $31.72M for Q4 2025.